Brad Margus currently leads Cerevance, a clinical-stage biopharmaceutical company he co-founded three years ago to advance new therapeutics for neurological and psychiatric diseases.

Concurrent with his business career, for the last 20+ years, Margus has worked as founder and volunteer Chair of the A-T Children’s Project, a non-profit that orchestrates research on a rare, brutal, genetic disease -- ataxia telangiectasia or "A-T" -- that two of his sons have. A-T causes progressive loss of muscle control, cancer and immune system problems.

He also currently serves on the Boards of Arvinas (Nasdaq: ARVN), a protein degradation company, and Presage Biosciences, a cancer company. He continues to serve as a Harvard Business School Global Advisor and as a member of three National Institutes of Health committees: the National Center for Advancing Translational Sciences Advisory Council, the Cure Acceleration Network Review Board, and as the Chair of the Network for Excellence in Neuroscience Clinical Trials External Oversight Board. He also sits on the Board of Global Genes, a non-profit organization that supports advocates for all rare diseases.